微小残留病
内科学
实时聚合酶链反应
医学
髓系白血病
胃肠病学
染色体易位
骨髓
预测值
诱导疗法
肿瘤科
完全缓解
髓样
生物
化疗
基因
生物化学
作者
Harmony Leroy,Stéphane de Botton,Nathalie Grardel,Stéphane Darre,Xavier Leleu,Christophe Roumier,Frank Morschhauser,Jean-Luc Laı̈,F Bauters,Pierre Fenaux,Claude Preudhomme
出处
期刊:Leukemia
[Springer Nature]
日期:2005-01-27
卷期号:19 (3): 367-372
被引量:116
标识
DOI:10.1038/sj.leu.2403627
摘要
Despite the favorable prognosis of patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22) translocation, relapses still occur in about 30% of the cases but no initial factors can strongly predict the risk of relapse. Several recent studies suggest that monitoring minimal residual disease (MRD) may identify patients at risk of relapse. We prospectively monitored AML1-ETO rearrangement by real-time quantitative PCR (RQ-PCR) in 21 patients uniformly treated in our center. Blood (PB) and bone marrow (BM) samples were collected during and after therapy. At diagnosis, levels of AML1-ETO transcript showed large variations and there was a trend for a higher relapse rate in patients with high pretreatment expression levels (P=0.065). After induction therapy, absolute transcript levels (below 10(-3), compared to Kasumi cell line), or a greater than 3 log decrease by comparison to diagnosis levels, were significant predictors of the absence of relapse (P=0.02 and P=0.02, respectively). MRD levels after consolidation therapy were also significant indicators of relapse (P=10(-5)). Comparison of BM and PB samples showed similar sensitivity for detecting AML1-ETO transcript. In conclusion, RQ-PCR appears to be an early predictive factor of the relapse risk in AML with t(8;21). PB samples can be used adequately to evaluate the level of MRD by this technique.
科研通智能强力驱动
Strongly Powered by AbleSci AI